Recurring epidemics of pharmaceutical drug abuse in America: Time for an all-drug strategy
D. Herzberg,
H. Guarino,
P. Mateu-Gelabert and
A.S. Bennett
American Journal of Public Health, 2016, vol. 106, issue 3, 408-410
Abstract:
Observers describe today's "epidemic" of pharmaceutical drug abuse as a recent phenomenon, but we argue that it is only themost recent of three waves stretching back more than a century. During each wave, policies have followed a similar pattern: voluntary educational campaigns, followed by supply-side policing and\-sometimes\-public health responses that would today be understood as "harm reduction." These experiences suggest that only broad-based application of all three approaches to users of all drugs (not just pharmaceutical drugs) can produce a reduction in drug-related harm rather than merely shifting it from one type of drug to another. This has rarely happened because policy has been shaped by the racially chargeddivisionof drug users into deserving and morally salvageable victims, or fearsome and morally repugnant criminals.
Keywords: naloxone; prescription drug, drug overdose; epidemic; harm reduction; human; Opioid-Related Disorders; public health service, Drug Overdose; Epidemics; Harm Reduction; Humans; Naloxone; Opioid-Related Disorders; Prescription Drugs; Public Health Practice (search for similar items in EconPapers)
Date: 2016
References: Add references at CitEc
Citations:
Downloads: (external link)
http://hdl.handle.net/10.2105/AJPH.2015.302982
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:aph:ajpbhl:10.2105/ajph.2015.302982_4
DOI: 10.2105/AJPH.2015.302982
Access Statistics for this article
American Journal of Public Health is currently edited by Alfredo Morabia
More articles in American Journal of Public Health from American Public Health Association
Bibliographic data for series maintained by Christopher F Baum ().